Authors: Raza, A Meyer, P Dutt, D Zorat, F Lisak, L Nascimben, F du Randt, M Kaspar, C Goldberg, C Loew, J Dar, S Gezer, S Venugopal, P Zeldis, J

Citation: A. Raza et al., Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes, BLOOD, 98(4), 2001, pp. 958-965

Authors: Preisler, HD Venugopal, P Gregory, SA Hsu, WT Loew, J Adler, S Gezer, S Creech, S Galvez, A Slivnick, D Andric, T Larson, RA Jajeh, A

Citation: Hd. Preisler et al., Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine), LEUK RES, 24(8), 2000, pp. 671-680

Authors: Raza, A Qawi, H Lisak, L Andric, T Dar, S Andrews, C Venugopal, P Gezer, S Gregory, S Loew, J Robin, E Rifkin, S Hsu, WT Huang, RW

Citation: A. Raza et al., Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone, BLOOD, 95(5), 2000, pp. 1580-1587

Authors: Preisler, HD Gao, XZ Ming, T Li, BR Bi, SC Devemy, E Loew, J Raza, A

Citation: Hd. Preisler et al., Marrow cytokine transcripts and the secondary hematologic disorders, LEUK LYMPH, 35(3-4), 1999, pp. 297-302

Authors: Goyal, R Qawi, H Ali, I Dar, S Mundle, S Shetty, V Mativi, Y Allampallam, K Lisak, L Loew, J Venugopal, P Gezer, S Robin, E Rifkin, S Raza, A

Citation: R. Goyal et al., Biologic characteristics of patients with hypocellular myelodysplastic syndromes, LEUK RES, 23(4), 1999, pp. 357-364